Chronic Cutaneous Lupus Erythematosus

Sticherling, Michael

doi:10.1007/3-211-27377-8_9

Cited by 3 publications

(10 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although this may apply to the majority of cases, scrutinous examinations have to be performed to exclude systemic LE as discoid lesions may be found in SLE and are consequently included in the list of ACR criteria. The most common entity is the discoid LE (DLE) (BOX 4) (FIGURE 2) [7][8][9][10]. No precise data on incidence are available; however, underestimation should be anticipated, as DLE may easily be confused with other more common skin diseases.…”

Section: Chronic Cutaneous Lupus Erythematosusmentioning

confidence: 98%

“…A total of 60% of DLE patients demonstrate an involvement of the scalp that results in permanent alopecia, whereas 10% of cases may present with scalp lesions alone [7,9,10,11]. This restricted form is in contrast with a generalized form with plaques below the neck and on the trunk.…”

Section: Chronic Cutaneous Lupus Erythematosusmentioning

confidence: 99%

“…A more follicular distribution with small erythematous papules of less than 1-cm diameter is referred to as follicular DLE. It is mainly located on the elbows but can be found at any other location [7,10]. Another distinct entity that may present as a single manifestation or together with other DLE manifestations is mucosal DLE, which can be found in up to 25% of patients [12][13][14].…”

Section: Chronic Cutaneous Lupus Erythematosusmentioning

confidence: 99%

“…From a dermatological viewpoint, skin involvement is not adequately reflected by these criteria. Three basic dermatologically distinct entities with various subsets can be defined with varying relation to systemic disease: chronic cutaneous LE (CCLE), subacute cutaneous LE (SCLE) and acute cutaneous LE (ACLE) (BOX 2) (FIGURE 1) [5][6][7][8][9][10]. Further clinical evaluation will show systemic involvement only very rarely in CCLE, whereas many SCLE patients fulfill up to four ACR criteria for SLE, and ACLE represents the inflammatory skin rash characteristic for SLE.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Cutaneous lupus erythematosus: clinical features, prognosis and laboratory findings

Sticherling

2006

Expert Review of Dermatology

Self Cite

View full text Add to dashboard Cite

The skin is one of the major organs involved in systemic lupus erythematosus (SLE) and may provide the first sign of the disease. Cutaneous manifestations comprise various specific and nonspecific symptoms that can be isolated or combined and are not amply reflected by currently available scoring systems. From the dermatological viewpoint, three distinct subsets of cutaneous lupus erythematosus can be defined that include chronic cutaneous lupus erythematosus (CCLE), subacute cutaneous lupus erythematosus (SCLE) and acute cutaneous lupus erythematosus. These, in turn, comprise different subsets and result in a heterogenous group of diseases. Based on case history, clinical and laboratory data, as well as organ imaging examinations, they need to be differentiated for prognostic and therapeutic reasons. Whereas CCLE rarely develops into SLE, SCLE and SLE are more closely related. Basic laboratory examinations should be performed on all patients at first diagnosis, whereas specific laboratory examinations will depend on individual data. Altogether, monitoring of lupus erythematosus (LE) patients for internal organ manifestations at any stage of their disease is mandatory. Even in seemingly isolated cutaneous LE, other LE entities should be excluded. Therapy should be initiated in an individually tailored way as either topical external or systemic treatment based on the extent and severity of organ involvement and should be regularly adapted. Thus, both dermatologists and rheumatologists should cooperate to provide optimal patient care.

show abstract

Section: Chronic Cutaneous Lupus Erythematosusmentioning

confidence: 98%

Section: Chronic Cutaneous Lupus Erythematosusmentioning

confidence: 99%

Section: Chronic Cutaneous Lupus Erythematosusmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Cutaneous lupus erythematosus: clinical features, prognosis and laboratory findings

Sticherling

2006

Expert Review of Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Neben topischen und läsionalen Therapeutika wie Glukokortikoiden kommen zahlreiche Systemtherapeutika zum Einsatz [1,2]. Zu den für die Indikation (systemischer) Lupus erythematodes zugelassenen Medikamenten zählen neben den Antimalariamitteln Chloroquin und Hydroxychloroquin Dapson und Azathioprin; daneben werden Methotrexat, Leflunomid, Ciclosporin A, Mycophenolat Mofetil, Sulfasalazin, Retinoide, Thalidomid sowie Clofazimin eingesetzt, für die eine entsprechende Zulassung nicht vorliegt.…”

Section: Diskussionunclassified

Successful therapy of discoid lupus erythematosus with efalizumab

et al. 2009

View full text Add to dashboard Cite

The therapy of discoid lupus erythematosus (DLE) is occasionally a therapeutic challenge. Topical treatment is often not sufficient and therapy with antimalarials [(hydroxy-) chloroquine] not always successful. We report on a 50-year-old male patient with recalcitrant chronic DLE who experienced within 12 weeks at first improvement and then almost complete remission for 11 months after off-label application of the anti-CD11a antibody efalizumab.

show abstract

Diagnostic approach and treatment of cutaneous lupus erythematosus

Sticherling¹,

Bonsmann

Kuhn³

2008

J Deutsche Derma Gesell

Self Cite

View full text Add to dashboard Cite

SummaryCutaneous lupus erythematosus (CLE) is a heterogeneous disorder with a wide range of skin manifestations. In the second part of this review, diagnostic procedures and treatment options in CLE are summarized.The diagnosis of the various subtypes of CLE is based on patients´s history,clinical findings,laboratory features, and histological and immunofluorescent examinations of skin biopsies. In case of systemic organ involvement, further adequate technical investigations are necessary. The therapy has to be adjusted to the subtype of CLE and its inflammatory activity as well as the extent of skin involvement. The skin manifestations of CLE are primarily treated by topical therapy, such as glucocorticosteroids, in combination with antimalarials. The response of CLE to immunosuppressive drugs that control organ involvement in systemic lupus erythematosus is often disappointing. Recent advances in biotechnology resulted in the development of several novel systemic agents for the treatment of autoimmune diseases; however, controlled clinical trials are still necessary for the approval of new therapies in CLE.

show abstract

Chronic Cutaneous Lupus Erythematosus

Cited by 3 publications

References 76 publications

Cutaneous lupus erythematosus: clinical features, prognosis and laboratory findings

Cutaneous lupus erythematosus: clinical features, prognosis and laboratory findings

Successful therapy of discoid lupus erythematosus with efalizumab

Diagnostic approach and treatment of cutaneous lupus erythematosus

Contact Info

Product

Resources

About